Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F09%3A00034200" target="_blank" >RIV/00216224:14110/09:00034200 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma
Original language description
Abstract: Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene andcutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment(odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical
International Journal of Clinical and Experimental Pathology
ISSN
1936-2625
e-ISSN
—
Volume of the periodical
2/2009
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
—
UT code for WoS article
—
EID of the result in the Scopus database
—

Similar results(10)